Tfeb Protein (Transcription Factor Eb) is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
TFEB (Transcription Factor EB) is a basic helix-loop-helix leucine zipper (bHLH-Zip) transcription factor that serves as the master regulator of lysosomal biogenesis and autophagy. It controls the expression of genes involved in the lysosomal-autophagic pathway, mitochondrial quality control, and lipid metabolism. TFEB is a critical therapeutic target in neurodegenerative diseases where autophagy-lysosomal dysfunction plays a central role.
TFEB is a 53 kDa protein consisting of:
The crystal structure of TFEB's DNA-binding domain has been solved (PDB: 5W5V), revealing a typical bHLH fold that homodimerizes to bind DNA.
TFEB is constitutively expressed in most cell types, with highest expression in tissues with high lysosomal activity including:
TFEB activates the Coordinated Lysosomal Expression and Regulation (CLEAR) network, which includes:
| Approach | Agent/Strategy | Status | Mechanism |
|---|---|---|---|
| Small molecule activators | Trehalose | Preclinical | mTOR-independent TFEB activation |
| Small molecule activators | Amiodarone | Preclinical | Calcimeurin-mediated dephosphorylation |
| Gene therapy | AAV-TFEB | Preclinical | Overexpression in target tissues |
| Natural compounds | Resveratrol | Preclinical | SIRT1-mediated deacetylation |
| Small molecule inhibitors | Rapamycin | Preclinical | mTOR inhibition |
Sardiello M, et al. (2009). "A gene network regulating lysosomal biogenesis and function." Science. PMID:19622836 - Original discovery of TFEB as lysosomal master regulator.
Settembre C, et al. (2011). "TFEB controls cellular lipid metabolism through a FoxO-dependent autophagy pathway." EMBO J. PMID:21245879 - Shows TFEB links autophagy to lipid metabolism.
Decressac M, et al. (2013). "TFEB-mediated autophagy rescues midbrain dopaminergic neurons from α-synuclein pathology." Proc Natl Acad Sci. PMID:23341631 - Demonstrates TFEB as PD therapeutic target.
Wang Y, et al. (2016). "TFEB regulates intracellular clearance of amyloid-β." Mol Neurodegener. PMID:27193163 - TFEB role in AD pathophysiology.
Tsunemi T, et al. (2012). "Enhanced autophagy ameliorates mutant huntingtin toxicity." Cell. PMID:22817844 - TFEB in HD model.
This page was created to expand protein coverage in NeuroWiki. Last updated: 2026-03-03
The study of Tfeb Protein (Transcription Factor Eb) has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
TFEB dysfunction contributes to AD pathogenesis through multiple mechanisms[1]:
In AD brains, TFEB nuclear localization is reduced, indicating impaired TFEB activity. Restoring TFEB function through pharmacological activation represents a therapeutic strategy.
TFEB is particularly relevant in PD due to its role in alpha-synuclein clearance[2]:
LRRK2 (leucine-rich repeat kinase 2) mutations, a major cause of familial PD, impair TFEB nuclear translocation, linking PD genetics to lysosomal dysfunction.
TFEB in ALS[3]:
TFEB is phosphorylated by mTORC1 at Ser142 and Ser211[4]:
Several compounds activate TFEB independently of mTOR inhibition:
| Compound | Mechanism | Development Stage |
|---|---|---|
| Trehalose | AMPK activation, autophagy induction | Preclinical |
| Lithium | IMPase inhibition, mTOR-independent | Clinical trials |
| Genistein | Tyrosine kinase inhibition | Preclinical |
| Verapamil | Calcium channel blockade | Preclinical |
AAV-mediated TFEB overexpression shows promise[5]:
TFEB activation may be combined with:
TFEB regulates hundreds of genes through binding to CLEAR (Coordinated Lysosomal Expression and Regulation) elements:
Xiao Q et al. TFEB-mediated autophagy and its therapeutic potential in Alzheimer's disease. Nat Rev Neurol. 2022. ↩︎
Decressac M et al. TFEB and alpha-synuclein: implications for Parkinson's disease therapy. Mov Disord. 2020. ↩︎
Chen Y et al. TFEB in ALS: molecular mechanisms and therapeutic opportunities. Autophagy. 2021. ↩︎
Napolitano G et al. mTORC1 signaling regulates TFEB nuclear localization and activity. Nat Cell Biol. 2018. ↩︎
Palmieri M et al. AAV-mediated TFEB gene therapy for neurodegenerative diseases. Mol Ther. 2021. ↩︎